Additionally, expression of the genotypes VEGF-634 CC and VEGF-1498 TT were associated with significantly less grade 3 or 4 hypertension compared with the alternate genotypes [102], demonstrating the need for molecular characterization of tumors to maximize therapeutic benefit of anti-VEGF therapy. The gene discussed is VEGFA; the disease is Hypertension.